1.Shi, X., Dong, X., Zhai, J., Liu, X., Lu, D., Ni, Z., Wu, H., & Cai, K. (2021). Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer. Frontiers in oncology.
2.Lu, Di et al. “Classification of Metastatic and Non-Metastatic Thoracic Lymph Nodes in Lung Cancer Patients Based on Dielectric Properties Using Adaptive Probabilistic Neural Networks.” Frontiers in oncology vol. 11 640804. 5 Mar. 2021
3.Diao, Dingwei et al. “Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer.” Translational lung cancer research vol. 10,2 (2021): 926-935.
4.Lu, Di et al. “Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis.” Cancer management and research vol. 11 2677-2690. 2 Apr. 2019.
5.Feng, Siyang et al. “TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells.” Experimental cell research vol. 373,1-2 (2018): 44-56.
6.Shi, Xiaoshun et al. “IRGS: an immune-related gene classifier for lung adenocarcinoma prognosis.” Journal of translational medicine vol. 18,1 55. 4 Feb. 2020.
7.Lu, Di et al. “Clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma.” Cancer medicine vol. 9,10 (2020): 3455-3462.
8.Mai, Shijie et al. “Oesophageal squamous cell carcinoma-associated IL-33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase.” Cell proliferation vol. 54,2 (2021): e12960.
9.Ren P, Zhai J, Wang X, Yin Y, Lin Z, Cai K, Wang H. Inhibition of BPHL inhibits proliferation in lung carcinoma cell lines. Transl Lung Cancer Res. 2023 May 31;12(5):1051-1061. doi: 10.21037/tlcr-23-225. Epub 2023 May 29. PMID: 37323178; PMCID: PMC10261862 （IF：4.0）
10.Chen Z, Cai Y, Ou T, Zhou H, Li H, Wang Z, Cai K. Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019. J Cancer Res Clin Oncol. 2024 May 28;150(5):282. doi: 10.1007/s00432-024-05802-6. PMID: 38806867; PMCID: PMC11133219（IF：2.7）
11.Chen Z, Zhang X, Zhai J, Fan J, Cai Y, Ye T, Wang Z, Cai K. Global burden of esophageal cancer attributable to high BMI in 204 countries and territories: 1990-2019. Thorac Cancer. 2024 Mar;15(9):681-692. doi: 10.1111/1759-7714.15239. Epub 2024 Feb 5. PMID: 38316627; PMCID: PMC10961222.（IF：2.3）
12.Lu D, Wu X, Wu W, Wu S, Li H, Zhang Y, Yan X, Zhai J, Dong X, Feng S, Zhang X, Sun F, Wang S, Cai K. Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer. Cell Death Dis. 2023 Dec 19;14(12):843. doi: 10.1038/s41419-023-06329-3. PMID: 38114477; PMCID: PMC10730877.（IF：8.1）
13.Guo Q, Yu W, Tan J, Zhang J, Chen J, Rao S, Guo X, Cai K. Remodelin delays non-small cell lung cancer progression by inhibiting NAT10 via the EMT pathway. Cancer Med. 2024 Jun;13(11):e7283. doi: 10.1002/cam4.7283. PMID: 38826095; PMCID: PMC11145023.（IF：3.1）
14.Liu T, Zou B, He M, Hu Y, Dou Y, Cui T, Tan P, Li S, Rao S, Huang Y, Liu S, Cai K, Wang D. LncReader: identification of dual functional long noncoding RNAs using a multi-head self-attention mechanism. Brief Bioinform. 2023 Jan 19;24(1):bbac579. doi: 10.1093/bib/bbac579. PMID: 36575567.（IF：9.5）
15.Wang Y, Cao N, Cui X, Liu Z, Yuan X, Chen S, Xu H, Yi M, Ti Y, Zheng F, Cai K. Detection of circulating tumor cells using a microfluidic chip for diagnostics and therapeutic prediction in mediastinal neuroblastoma. Eur J Pediatr. 2024 Dec 20;184(1):93. doi: 10.1007/s00431-024-05896-7. PMID: 39702653.（IF：2.6）
16.Chen Z, Yang Z, Liu Y, Zhou Z, Men B, Yun L, Jiang J, Ge H, Dian M, He Y, Zhang R, Cai K, Rao X, Rao S. Jaceosidin overcomes osimertinib resistance in lung cancer by inducing G2/M cycle arrest through targeting DDB1. Toxicology and applied pharmacology. 2025 Jun;499:117327. doi: 10.1016/j.taap.2025.117327. Epub 2025 Apr 3. PMID: 40187661.（IF：3.4）
17.Wang Z, Cai Y, Tong Y, Li H, Zhou H, Ou T, Ye T, Zhang J, Cai K, Chen Z. Global, regional, and national burden of fracture of sternum and/or fracture of one or more ribs: a systematic analysis of incidence, YLDs with projections to 2030. Frontiers in public health. 2025 Apr 3;13:1565478. doi: 10.3389/fpubh.2025.1565478. PMID: 40247872; PMCID: PMC12003264.（IF：3.4）
18.Jiang J, Zhang Y, Men B, He Y, Yun L, Li F, Rao X, Cai K, Rao S. Prognostic Significance of R-Loops in Lung Adenocarcinoma: Implications for Immune Response and Drug Sensitivity. Cancer management and research. 2025 Aug 12;17:1625-1642. doi: 10.2147/CMAR.S533571. PMID: 40821703; PMCID: PMC12357588.（IF：2.6）
19.Dian M, Yun L, Meng Q, Lin S, Ji M, Zhou Y, Liu W, Yang Z, Zhao Y, Li G, Jiang J, Hao W, Chen Z, Zhou Z, Zhang R, Liu T, He Y, Yan T, Wang H, Cronin SJF, Penninger JM, Cai K, Rao S. Targeting DDX3X suppresses progression of KRAS-driven lung cancer by disrupting antioxidative homeostasis and inducing ferroptosis. Cell death & disease. 2025 Aug 30;16(1):660. doi: 10.1038/s41419-025-07980-8. PMID: 40885716; PMCID: PMC12398621.（IF：9.6）